CMO Doyle Mittie Trades 1,000 Shares Each of Avalo Therapeutics – Buying Low, Selling High in 10b5‑1 Plan Flash

Insider Activity Spotlight: Doyle Mittie’s Recent Trades at Avalo Therapeutics

In a tightly‑structured Rule 10b5‑1 plan, Chief Medical Officer Doyle Mittie executed a modest 1,000‑share purchase at $12.65 and a simultaneous 1,000‑share sale at $20.00 on July 27, 2026. The same day he also sold 1,000 rights to purchase stock at no cost, increasing his post‑transaction ownership to 124,750 shares. The trades are part of a broader pattern of systematic buying and selling that has unfolded over the past five months.

What the Numbers Say for Investors

The buy and sell prices diverge sharply from the market close ($19.52) and the current 52‑week high ($24.27). While the 10b5‑1 plan guarantees the trades were pre‑arranged, the price spread hints at strategic timing: buying below the recent highs and selling near or above the mid‑cycle range. For investors, this suggests the insider is actively managing risk—locking in gains from earlier purchases while taking advantage of a favorable valuation window. If the market continues its upward momentum (a 52‑week gain of 140.94%), the CMO’s net position could become a bullish signal, potentially buoying share demand.

A Pattern of Balanced Trading

Mittie’s transaction history reveals a disciplined, cycle‑driven approach. Since April, he has alternated between sizable buys at low single‑digit prices (e.g., $8.04) and sales at multi‑digit prices (up to $22.88), often timing sales around quarterly earnings or clinical milestones. The most recent 10b5‑1 trades align with this rhythm: a buy at $12.65 (mid‑cycle) and a sell at $20.00 (near the recent peak). His net shareholding has hovered around 55,000–125,000 shares, indicating he maintains a substantial, yet not dominating, stake. The pattern of selling options after vesting also points to a strategy of realizing gains from equity awards while preserving core ownership.

Implications for Avalo’s Future

Avalo’s pipeline, centered on immunology and rare genetic diseases, is still in the early stages of clinical validation. The company’s market cap of $1.03 billion and a negative P/E of –3.7 reflect high growth expectations and valuation pressure. Insider activity that balances buying and selling can be reassuring: it signals confidence in the company’s trajectory while managing liquidity risk. However, the consistent sales during price highs also suggest a conservative risk posture, which could temper enthusiasm among speculative investors. For long‑term holders, the steady accumulation of shares—especially at lower price points—reinforces a belief in Avalo’s eventual breakthrough.

Profiling Doyle Mittie

Mittie’s tenure as CMO has been marked by a disciplined trade schedule, reflecting a long‑term investment philosophy. His trades show a clear preference for buying in the mid‑to‑low range and selling near or above recent highs, a tactic that balances potential upside with risk mitigation. The use of a Rule 10b5‑1 plan further underscores his commitment to transparency and adherence to regulatory best practices. As Avalo moves toward pivotal clinical milestones, investors should watch how Mittie’s actions evolve—particularly any shift toward larger purchases or a reduction in option sales— as these could signal shifting confidence levels or strategic realignment within the company’s leadership.